ISCC–NBS system

Nexstim Releases the New NBS5+ in the United States

Retrieved on: 
Friday, October 22, 2021
Depression, Technology, Hospital, NTM, Speech, Neurological disorder, FDA, NBS, ISCC–NBS system, Brain, Marketing, Mental health, CEO, TMS, CE, Transcranial magnetic stimulation, Nasdaq, MDD, PLC, Lists of diseases, Medical device, Medical imaging

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the launch of a new navigated transcranial magnetic stimulation (nTMS) system configuration in the United States, to further strengthen competitive advantage in this market.

Key Points: 
  • Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the launch of a new navigated transcranial magnetic stimulation (nTMS) system configuration in the United States, to further strengthen competitive advantage in this market.
  • Nexstims proprietary NBT system is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States.
  • In addition, Nexstim is commercializing its SmartFocus based Navigated Brain Stimulation (NBS) system for diagnostic applications.
  • Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.